The FDA on 15 September 2026 told consumers not to buy or use two products sold for weight loss, LUZE Fit Intensity and Beauty 911, after its laboratory found sibutramine in both. Neither label lists it. Sibutramine was the active ingredient in Meridia, a prescription weight-loss drug whose approval the FDA withdrew in 2010 after a cardiovascular outcomes trial indicated an increased risk of heart attack and stroke. Anyone holding either product cannot tell from the packaging what they have been taking.
What the FDA found
The two notices were posted on the same day and are almost word for word the same. Each describes the product as promoted and sold for weight loss on various websites, including the Shop app at shop.app, and possibly in some retail stores. In each case FDA laboratory analysis confirmed sibutramine that was not on the label.
The agency describes sibutramine as a controlled substance that was removed from the market over safety concerns, and says it can significantly raise blood pressure or heart rate in some people. It singles out anyone with a history of heart disease, heart failure, an irregular heartbeat or stroke, and warns that the products may interact in life-threatening ways with other medicines. The notices do not say how much sibutramine was found, do not name a manufacturer or a lot, and are not recalls: they are public warnings, with a request that health professionals and consumers report any adverse events through MedWatch.
Why sibutramine in particular
The regulatory history is short and unusually clear. On 7 October 2010 the FDA asked Abbott Laboratories to withdraw Meridia voluntarily, based on its analysis of the Sibutramine Cardiovascular Outcomes Trial, known as SCOUT. Abbott agreed, and the withdrawal of approval took effect on 21 December 2010. In its Federal Register notice the agency said the drug’s benefits for weight loss and weight maintenance no longer outweighed the risks in any identifiable patient population.
That is what makes a hidden dose more than a labelling fault. When Meridia was sold, it was a prescription drug taken with a prescriber aware of it. Undeclared sibutramine in a product sold like a supplement reaches people who have no particular reason to have their blood pressure checked, at an amount nobody has disclosed, possibly alongside other medicines it interacts with.
These are not isolated finds. Before these two, the FDA’s list of weight-loss product notifications already carried seven entries dated 2026, the most recent for ZUBB Dietary Supplement on 4 September, and including Lipofit Extreme 2.0 Fat Burner in June. The FDA says on that page that the list covers only a small fraction of the contaminated products on the market, and that a product’s absence from it does not mean the product is safe. Products sold on the promise of drug-like weight loss without a prescription sit in the same marketplace, and our review of what weight-loss supplements actually contain sets out what the legitimate ingredients in that category can and cannot do.
What the notices do not tell us is how widely either product sold, whether any adverse events have been reported, or whether the listings are still live. The FDA can only warn about products it has tested.
Sources: FDA, LUZE Fit Intensity may be harmful due to hidden ingredient, 15 September 2026 · FDA, Beauty 911 may be harmful due to hidden ingredient, 15 September 2026 · FDA, Weight Loss Product Notifications, read 15 September 2026 · Federal Register 75 FR 80061, Abbott Laboratories, Inc.; Withdrawal of Approval of a New Drug Application for MERIDIA, 21 December 2010
